Abstract

Introduction:We investigated the feasibility of using a fluorescence resonance energy transfer system to image enzymatic activity in order to evaluate the effects of aliskiren (a direct renin inhibitor) on diabetic nephropathy.Materials and methods:First, we induced diabetes in C57BL/6J mice using streptozotocin, then treated them with either aliskiren (25 mg/kg/day) or the angiotensin type 1 receptor blocker valsartan (15 mg/kg/day) for four weeks. Finally, we utilized renin fluorescence resonance energy transfer substrate to assess renin activity.Results:Renin activity was much higher in the kidneys of diabetic mice compared to those of the non-diabetic control mice. While aliskiren inhibited this activity, valsartan did not. We noted that production of reactive oxygen species intensified and the bioavailability of nitric oxide diminished in the glomeruli of diabetic mice. Aliskiren and valsartan significantly ameliorated these effects. They suppressed glomerular production of reactive oxygen species and urinary albumin excretion. In fact, urinary albumin excretion in diabetic mice treated with aliskiren or valsartan was lower than that in untreated diabetic mice. Furthermore, aliskiren and valsartan significantly reduced glomerular permeability by maintaining the glomerular endothelial surface layer.Conclusion:Fluorescence resonance energy transfer could provide a new tool for evaluating tissue and plasma enzymatic activity.

Highlights

  • We investigated the feasibility of using a fluorescence resonance energy transfer system to image enzymatic activity in order to evaluate the effects of aliskiren on diabetic nephropathy

  • The STZ, STZ with aliskiren (STZ+Alis), and STZ with valsartan (STZ+Val) groups had significantly lower body weight and higher serum glucose and creatinine levels compared to mice in the control group

  • In vivo and in vitro evidence suggest that local tissue renin-angiotensin system (RAS) is activated in diabetes,[10,11,12,13,14] which may implicate it in the pathogenesis of diabetic nephropathy

Read more

Summary

Introduction

We investigated the feasibility of using a fluorescence resonance energy transfer system to image enzymatic activity in order to evaluate the effects of aliskiren (a direct renin inhibitor) on diabetic nephropathy. Results: Renin activity was much higher in the kidneys of diabetic mice compared to those of the non-diabetic control mice. While aliskiren inhibited this activity, valsartan did not. Aliskiren and valsartan significantly ameliorated these effects They suppressed glomerular production of reactive oxygen species and urinary albumin excretion. Systemic renin activity is suppressed in diabetes, renin-angiotensin system (RAS) inhibitors exert renoprotective effects.[2] This is possible because the pathogenesis of diabetic nephropathy appears to involve activation of local/tissue RAS (independently regulated in each organ). Inhibiting RAS activation is important in order to prevent the progression of diabetic nephropathy.[2]

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.